Dosage regimen of anti-LAG3 antibody and combination therapy with anti-PD-1 antibody to treat cancer

摘要

The present invention relates to dosing regimens of anti-LAG3 antibodies useful for the treatment of cancer. In particular, the present invention relates to a combination therapy comprising administering an antibody of programmed death 1 protein (PD-1) or programmed death ligand 1 (PD-L1) and an antibody of lymphocyte-activating gene 3 (LAG3). of the dosing regimen. The invention also includes administering to a patient an anti-LAG3 antibody and an anti-PD-1 antibody, wherein the tumor tissue section of the patient is positive for PD-L1 expression, and optionally is positive for LAG3 expression. provides